GENE ONLINE|News &
Opinion
Blog

2022-06-14| In-DepthSpecial

Ushering In A New Generation Of AI-Focused Investments Opportunities

by Reed Slater
Share To

Artificial intelligence (AI) has officially enamored the world with its plethora of potential applications. Optimistic folks see AI as a tool with the power to aid humanity and the technological revolution we live in. AI in the biotech sphere centers around drug discovery and drug repurposing. With a record number of AI-focused biotech companies forming, it is time to consider the applications, limitations, and the prospective future that investors face when confronted with AI startups looking for funding.

At the Digital Redefining Early Stage Investments (RESI) 2022 conference, Bill Kuziel, Ph.D. of MedPro Investors, sits down with three venture capital professionals to discuss the use of AI in biotechnology and its future during uncertain economic times. 

 

 

It's free! Log in now to read

LATEST
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
2023-03-24
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol
2023-03-23
Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.
2023-03-23
Scroll to Top